Re-Engineered Gleevec Reduces Heart Risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib — best known by its brand name Gleevec?– to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.The new study, which is slated to appear in the Dec. [click link for full article]

More: continued here

Filed under: GastroIntestinal / Gastroentorology on December 6th, 2007